Pure Global
NCT05835648

Effect of Dietary Fiber on Non-dialysis Patients With Chronic Kidney Disease

Effect of Dietary Fiber on Anemia and Glomerular Filtration Rate in Non-dialysis Patients With Chronic Kidney Disease
Qianfoshan Hospital·ClinicalTrials.gov·dietary supplementNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Kidney Disease
Drug/Device/Intervention
Nutrasumma
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Qianfoshan Hospital
Timeline & enrollment
Phase
N/A
Start date
Apr 30, 2023
End date
Apr 30, 2024
Enrollment
56 participants
Primary outcome

Changes in baseline hemoglobin levels at 9 months,Changes of glomerular filtration rate at baseline at 9 months

Summary

The main objective of this study was to investigate the effect of dietary fiber on anemia and
 glomerular filtration rate in non-dialysis patients with chronic kidney disease. Participants
 will be randomly divided into a dietary fiber intervention group and a blank control group.
 The patients in the dietary fiber intervention group will have dietary fiber intake survey
 conducted by dietitians on the basis of basic treatment. Supplemented dietary fiber was given
 on the basis of daily diet, once a day, 1 piece each time, before meals, and the intervention
 lasted for 3 months. The blank control group was followed up without intervention. Clinical
 data, blood, urine and stool samples were collected at the initial diagnosis and at each
 follow-up site.

ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05835648
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05835648 through Pure Global AI's free database. This phase not specified trial is sponsored by Qianfoshan Hospital and is currently Not yet recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 56 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.